Resultats de la cerca - Hartmut Link

Refinar resultats
  1. 1
    Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF)

    Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF) per Hartmut Link

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Editorial
    Afegir a favorits
    Guardat en:
  2. 2
    Transplantation of allogeneic CD34+ blood cells

    Transplantation of allogeneic CD34+ blood cells per Hartmut Link, Lubomir Arseniev, O Bahre, JG Kadar, H. Diedrich, H. Poliwoda

    Publicat 1996
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Supportive Treatments for Patients with Cancer

    Supportive Treatments for Patients with Cancer per Karin Jordan, Petra Feyer, Ulrike Höller, Hartmut Link, Bernhard Wörmann, Franziska Jahn

    Publicat 2017
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  4. 4
    Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study

    Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study per Georg Maschmeyer, Hartmut Link, Wolfgang Hiddemann, Peter Meyer, M. Helmerking, Edith Eisenmann, Josef Schmitt, Dieter Adam

    Publicat 1994
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    A controlled trial of recombinant human erythropoietin after bone marrow transplantation

    A controlled trial of recombinant human erythropoietin after bone marrow transplantation per Hartmut Link, MA Boogaerts, AA Fauser, S Slavin, J Reiffers, NC Gorin, Carella Am, Franco Mandelli, Stefan Burdach, Augustin Ferrant

    Publicat 1994
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    A controlled trial of recombinant human granulocyte-macrophage colony- stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma

    A controlled trial of recombinant human granulocyte-macrophage colony- stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplan... per Hartmut Link, MA Boogaerts, Carella Am, Augustin Ferrant, Helmut Gadner, NC Gorin, I. Harabacz, JL Harousseau, P Hervé, Johanna Holldack

    Publicat 1992
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group

    Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group per Pierre Fenaux, M. Le Deley, Sylvie Castaigné, E Archimbaud, Christine Chomienne, Hartmut Link, A. Guerci, M Duarte, MT Daniel, Deborah A. Bowen

    Publicat 1993
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations

    Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations per Matti Aapro, Ralph V. Boccia, Robert Leonard, Carlos Camps, Mario Campone, Sylvain Choquet, Marco Danova, John A. Glaspy, Iwona Hus, Hartmut Link, Thamer Sliwa, Hans Tesch, Vicente Valero

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  9. 9
    A German multicenter, randomized phase III trial comparing irinotecan–carboplatin with etoposide–carboplatin as first-line therapy for extensive-disease small-cell lung cancer

    A German multicenter, randomized phase III trial comparing irinotecan–carboplatin with etoposide–carboplatin as first-line therapy for extensive-disease small-cell lung cancer per Alexander Schmittel, Martin Sebastian, Ludwig Fischer von Weikersthal, Peter Martus, Thomas Gauler, Christoph C. Kaufmann, P. Hortig, J.R. Fischer, Hartmut Link, D. Binder, B. Fischer, K Caca, Wilfried Eberhardt, Ulrich Keilholz

    Publicat 2011
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines

    Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines per Matti Aapro, Yves Béguin, Carsten Bokemeyer, Mario Dicato, Pere Gascón, John A. Glaspy, Axel Hofmann, Hartmut Link, T. Littlewood, Heinz Ludwig, Anders Österborg, P. Pronzato, Valeria Santini, D. Schrijvers, R. Stauder, Kim Jordan, Jørn Herrstedt

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Iron metabolism and iron supplementation in cancer patients

    Iron metabolism and iron supplementation in cancer patients per Heinz Ludwig, Rayko Evstatiev, Gabriela Kornek, Matti Aapro, Thomas Bauernhofer, Veronika Buxhofer‐Ausch, Michael Fridrik, D. Geißler, Klaus Geißler, Heinz Gisslinger, Elisabeth Koller, Gerhard Kopetzky, Alois Lang, Holger Rumpold, Michael Steurer, Houman Kamali, Hartmut Link

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  12. 12
    Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial

    Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial per G. Huebner, Hartmut Link, C.-H. Köhne, Michael Stahl, Albrecht Kretzschmar, Silke Steinbach, Gunnar Folprecht, H. Bernhard, Salah‐Eddin Al‐Batran, Patrick Schöffski, Christoph Burkart, Frank Kullmann, Burkhard Otremba, M Menges, Martin Hoffmann, Ulrich Kaiser, Ali Aldaoud, Andreas Jahn

    Publicat 2008
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Safety and Cost Effectiveness of a 10 × 109/L Trigger for Prophylactic Platelet Transfusions Compared With the Traditional 20 × 109/L Trigger: A Prospective Comparative Trial in 105 Patients With Acute Myeloid Leukemia

    Safety and Cost Effectiveness of a 10 × 109/L Trigger for Prophylactic Platelet Transfusions Compared With the Traditional 20 × 109/L Trigger: A Prospective Comparative Trial in 10... per Hannes Wandt, Markus H. Frank, Gerhard Ehninger, Christiane Schneider, N. Brack, Ali Daoud, I. Fackler-Schwalbe, J.T. Fischer, Ringfried Gäckle, Thomas Geer, P. Harms, B. Löffler, S. Öhl, Burkhard Otremba, Monika Raab, Petra Schönrock-Nabulsi, Gerhard Strobel, Rolf Winter, Hartmut Link

    Publicat 1998
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

    Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society... per Werner Heinz, Dieter Buchheidt, Maximilian Christopeit, Marie von Lilienfeld‐Toal, Oliver A. Cornely, Hermann Einsele, Meinolf Karthaus, Hartmut Link, Rolf Mahlberg, Silke Neumann, Helmut Ostermann, Olaf Penack, Markus Ruhnke, Michael Sandherr, Xaver Schiel, Jörg Janne Vehreschild, Florian Weißinger, Georg Maschmeyer

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  15. 15
    Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies

    Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies per Hermann Einsele, Hartmut Bertz, J. Beyer, Michael Kiehl, Volker Runde, Hans-Jochen Kölb, Ernst Holler, Robert Beck, Rainer Schwerdfeger, Ulrike Schumacher, Holger Hebart, Hans Martin, Joachim Kienast, Andrew J. Ullmann, Georg Maschmeyer, William Krüger, Dietger Niederwieser, Hartmut Link, Christian Schmidt, Helmut Oettle, Thomas Klingebiel

    Publicat 2003
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

    Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology... per Sabine Mousset, Dieter Buchheidt, Werner Heinz, Markus Ruhnke, Oliver A. Cornely, Gerlinde Egerer, William Krüger, Hartmut Link, Silke Neumann, Helmut Ostermann, Jens Panse, Olaf Penack, Christina Rieger, Martin Schmidt‐Hieber, Gerda Silling, Thomas Südhoff, Andrew J. Ullmann, Hans‐Heinrich Wolf, Georg Maschmeyer, Angelika Böhme

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015

    Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer.... per C.-H. Köhne, Jacques De Grève, J. T. Hartmann, István Láng, Philippe Vergauwe, Karl‐Friedrich Becker, D. Braumann, E. Joosens, Lothar Müller, Jos Janssens, Carsten Bokemeyer, Peter Reimer, Hartmut Link, E. Späth‐Schwalbe, H. Wilke, Harry Bleiberg, Jan Van den Brande, Muriel Debois, Ullrich Bethe, Eric Van Cutsem

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase

    Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase per Mohamad Jawhar, Nicole Naumann, Juliana Schwaab, H. Baurmann, Jochen Casper, Tu‐Anh Dang, Lutz Dietze, Konstanze Döhner, Annette Hänel, B. Lathan, Hartmut Link, Sina Lotfi, Ole Maywald, Stephan Mielke, Lothar Müller, Uwe Platzbecker, Otto Prümmer, Henrike Thomssen, Karin Töpelt, Jens Panse, Tom Vieler, Wolf‐Karsten Hofmann, Torsten Haferlach, Claudia Haferlach, Alice Fabarius, Andreas Hochhaus, Nicholas C.P. Cross, Andreas Reiter, Georgia Metzgeroth

    Publicat 2017
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    S3-Leitlinie Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs – Langversion 2.0 – August 2019. AWMF-Registernummer: 032/009OL

    S3-Leitlinie Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs – Langversion 2.0 – August 2019. AWMF-Registernummer: 032/009... per Markus Moehler, Salah-Edin Al-Batran, Tilo Andus, Jann Arends, Dirk Arnold, Gustavo Baretton, Jan Bornschein, Wilfried Budach, S Daum, Christoph G. Dietrich, Matthias Ebert, Wolfgang Fischbach, Michael Flentje, Ines Gockel, Lars Grenacher, Jörg Haier, Stefan Höcht, R Jakobs, Christian Jenssen, Barbara Kade, S Kanzler, Jost Langhorst, Hartmut Link, Florian Lordick, Dietmar Lorenz, Sylvie Lorenzen, Manfred P. Lutz, Helmut Messmann, Hans‐Joachim Meyer, Stefan Mönig, Katja Ott, Michael Quante, Christoph Röcken, Peter Schlattmann, Wolff-H. Schmiegel, A. Schreyer, Andrea Tannapfel, Peter Thuss‐Patience, Arved Weimann, Susanne Unverzagt

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial

    Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial per Christoph Röllig, Hubert Serve, Richard Noppeney, Maher Hanoun, Utz Krug, Claudia D. Baldus, Christian Brandts, Volker Kunzmann, Hermann Einsele, Alwin Krämer, Carsten Müller‐Tidow, Kerstin Schäfer‐Eckart, Andreas Neubauer, Andreas Burchert, Aristoteles Giagounidis, Stefan W. Krause, Andréas Mackensen, Walter E. Aulitzky, Regina Herbst, Mathias Hänel, Norbert Frickhofen, Johannes Kullmer, Ulrich Kaiser, Alexander Kiani, Hartmut Link, Thomas Geer, Albrecht Reichle, Christian Junghanß, Roland Repp, Achim Meinhardt, Heinz Dürk, Ina‐Maria Klut, Martin Bornhäuser, Markus Schaich, Stefani Parmentier, Martin Görner, Christian Thiede, Malte von Bonin, Uwe Platzbecker, Johannes Schetelig, Michael Krämer, Wolfgang E. Berdel, Gerhard Ehninger

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: